Markets:

Overview

News

Currencies

International

Treasuries

Cyteir Therapeutics, Inc. - Common Stock (NQ:CYT)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Cyteir Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >

Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq

March 07, 2024

From Cyteir Therapeutics

Via Business Wire

Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile

October 12, 2023

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics (NASDAQ: CYT) to Dissolve After Discontinuing Development of CYT-0851

June 30, 2023

Cyteir Announces Halt of CYT-0851 Development and Company Dissolution Biotech firm Cyteir Therapeutics, Inc. (NASDAQ: CYT) announced today its decision

Via Spotlight Growth

Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution

June 30, 2023

From Cyteir Therapeutics

Via Business Wire

Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile

June 03, 2023

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights

May 10, 2023

From Cyteir Therapeutics, Inc.

Via Business Wire

Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

March 23, 2023

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer

February 06, 2023

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway

January 19, 2023

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights

November 07, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium

October 12, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

August 31, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights

August 08, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

August 01, 2022

From Cyteir Therapeutics

Via Business Wire

CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies

June 05, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

May 31, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Reports First Quarter 2022 Financial Results and Operational Highlights

May 05, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics to Participate in the 2022 Bank of America Healthcare Conference

May 04, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality

May 03, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Names Adam Veness General Counsel

April 25, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics to Host Virtual Research and Development (R&D) Day on April 26, 2022

April 18, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

March 16, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Announces the Appointment of Stephen Sands to Board of Directors

February 24, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851

February 08, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Announces the Appointment of John F. Thero to Board of Directors

February 07, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial With CYT-0851

January 12, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

January 03, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of Directors

December 16, 2021

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

November 12, 2021

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics to Participate in the Credit Suisse 30th Annual Healthcare Conference

November 01, 2021

From Cyteir Therapeutics

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.